CN115444817A - Nanometer abiraterone acetate composition and preparation method and application thereof - Google Patents
Nanometer abiraterone acetate composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN115444817A CN115444817A CN202110643127.5A CN202110643127A CN115444817A CN 115444817 A CN115444817 A CN 115444817A CN 202110643127 A CN202110643127 A CN 202110643127A CN 115444817 A CN115444817 A CN 115444817A
- Authority
- CN
- China
- Prior art keywords
- abiraterone acetate
- composition
- nano
- abiraterone
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004103 abiraterone acetate Drugs 0.000 title claims abstract description 130
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title claims abstract description 130
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 59
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000003085 diluting agent Substances 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000000375 suspending agent Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 4
- 238000000227 grinding Methods 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 6
- 229960001021 lactose monohydrate Drugs 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- 229960000878 docusate sodium Drugs 0.000 claims description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 41
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 239000002994 raw material Substances 0.000 description 15
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000012467 final product Substances 0.000 description 11
- 229920003081 Povidone K 30 Polymers 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 9
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 8
- 229960000853 abiraterone Drugs 0.000 description 8
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 7
- 239000006070 nanosuspension Substances 0.000 description 7
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 6
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- 238000003801 milling Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000009246 food effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000021471 food effect Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 102220042174 rs141655687 Human genes 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940124766 Cyp17 inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses a nanometer abiraterone acetate composition and a preparation method thereof, wherein the nanometer abiraterone acetate composition comprises the following components in percentage by weight: (0.1-0.5): (0.05-0.5): (5-25): (5-25): (0-1) abiraterone acetate, a suspending agent, a surfactant, an antioxidant, a solvent and a diluent; the D90 of the abiraterone acetate is less than or equal to 1000nm. The nanometer abiraterone acetate composition has small abiraterone acetate particle size, can obviously improve the bioavailability of the abiraterone acetate, and promotes the rapid absorption of the medicine in the body; the preparation method has simple process and high success rate. The invention also discloses a medicine containing the nano abiraterone acetate composition, which can improve the bioavailability of the abiraterone acetate. The nano abiraterone acetate composition disclosed by the invention can be applied to treating prostate cancer, reduce dosage, reduce adverse reactions and improve individual difference when the abiraterone acetate is taken.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a nano abiraterone acetate composition and a preparation method and application thereof.
Background
Abiraterone acetate, available under the name abiraterone acetate and under the name
The Chinese name "zeke" is American vitality (Johnson)&Johnson) pharmaceutical company. The structural formula is shown as a formula I.
Abiraterone acetate reduces androgen levels by inhibiting the key enzyme in androgen synthesis, CYP450C17, which can be used in combination with prednisone (prednisone) for the treatment of patients with metastatic potential prostate tumors. Abiraterone acetate was first approved for marketing in 2011 by the Food and Drug Administration (FDA) and then marketed in various countries and regions throughout the world including china, the european union, japan, and so on.
The abiraterone acetate is converted into the abiraterone with biological activity through deacetylation after entering a human body. Abiraterone acetate is a lipophilic compound, which is highly soluble in organic solvents but hardly soluble in water and poorly permeable, belonging to BCS class 4, with a bioavailability of less than 10%, and is therefore administered at a dose of 1000mg (250 mg/tablet x 4 tablets). At the same time, abiraterone acetate also has obvious food effect: the patients were asked to take the medication in the fasting state and to maintain the fasting state not only for 2 hours before the medication was taken but also for 1 hour after the medication was taken. These above problems all indicate that the product is at a safety risk: the improvement of bioavailability and individuality of the medicine by means of preparation is the direction pursued by pharmaceutical people at present, such as hepatotoxicity, food effect, individuality difference, large daily dose (1000 mg), etc.
According to the current literature reports, there are 2 methods for improving the oral bioavailability of abiraterone acetate, namely changing the physicochemical property of the drug, improving the membrane permeability or improving the dissolution property of the drug, such as micronization technology, solid dispersion technology, inclusion technology and the like.
Patent CN103446069A discloses an abiraterone oral solid composition and a preparation method thereof, wherein abiraterone acetate raw material medicine is subjected to micronization treatment, the particle size is controlled within a range of 0-20 μm to improve the dissolution rate of tablets, but after research, the raw material medicine is independently micronized and can not obviously improve the dissolution rate, and special equipment is required for crushing to the particle size range.
Patent CN102743393A discloses a medicinal composition containing abiraterone acetate and a preparation process thereof, wherein the abiraterone acetate and hydrophilic auxiliary materials are crushed according to a proportion, and the particle size of the raw material medicine is 10-30 μm, so that the dissolution rate and the bioavailability of the medicine are improved. However, even if the particle size of the raw material drug is micronized to 10-30um, the improvement of the drug dissolution rate is still limited, the dissolution rate is only 60% in a medium with pH4.5 and added with a surfactant for 15min, and the bioavailability is still very low.
Patent CN103070828a discloses a solid dispersion and tablet containing abiraterone acetate and a preparation method thereof, wherein the solid dispersion is prepared by mixing 1: dissolving 0.5-4 of abiraterone acetate and povidone in chloroform, drying under reduced pressure, adding into water, grinding, granulating, and drying. Although the dissolution rate is improved, the process needs to prepare a solid dispersion, uses chloroform as a solvent, does not utilize workshop safety production and labor protection of workers, has limited dissolution improvement, and has lower bioavailability because 64 percent of the solution is dissolved in a medium with pH4.5 and added with a surfactant for 10 min.
CN102961358A discloses an abiraterone acetate liquid capsule, the content comprises abiraterone acetate, solvent, antioxidant and fatty acid monoglyceride. The prescription components and the preparation process of the patent are complex, the preparation process needs further heating, the stability of the medicine is reduced, the medication safety is affected, and the problem of the bioavailability of the medicine cannot be solved.
CN110354094A discloses a CYP17 inhibitor soft capsule and a preparation method thereof, wherein abiraterone acetate is dissolved in fatty glyceride, and then the solution is filled into the soft capsule. Although some improvement in vivo dissolution and solubility was seen in the beagle in vivo data, prolonged gastrointestinal residence time, stimulated lymphatic transport, and reduced metabolic effects. However, since the soft capsule contains a large amount of fatty acid glyceride, the individual difference cannot be eliminated and the stability is poor.
In addition, the method for providing bioavailability is to reduce the particle size of the abiraterone acetate to a nanometer level, and when the particle size of the bulk drug reaches the nanometer level, the solubility and the membrane permeability are greatly improved due to the extremely large specific surface area of the bulk drug.
For example, patent WO2014009436 reports a nanosuspension containing abiraterone acetate or a derivative thereof, which increases the solubility of abiraterone acetate and improves the transmembrane capacity.
For another example, patent CN111617258a reports a method for preparing abiraterone or its derivative pharmaceutical composition, which comprises preparing abiraterone acetate and absorption enhancer into a nanosuspension, then adding excipient, granulating with fluidized bed to prepare abiraterone acetate nanoparticles, tabletting into micro-tablets, and encapsulating, to improve dissolution and bioavailability of the product, but still needs to reach 300mg per day, and fails to eliminate the effect of food on the product.
In conclusion, the existing abiraterone acetate medicinal preparation has the following defects: the dissolution rate is low, and the bioavailability is not high; the daily dose is large, with the risk of food effect and individualization differences.
Disclosure of Invention
In order to overcome the defects of the prior art, one of the purposes of the invention is to provide a nano abiraterone acetate composition, wherein the abiraterone acetate has a small particle size, and can remarkably improve the bioavailability of the abiraterone acetate and promote the rapid absorption of a medicine in a body.
The invention also aims to provide a preparation method of the nanometer abiraterone acetate composition, which is simple and convenient in process and high in success rate.
The invention also aims to provide a medicament containing the nano abiraterone acetate composition, which can obviously improve the bioavailability of the abiraterone acetate and promote the rapid absorption of the medicament in vivo.
The fourth purpose of the invention is to apply the nanometer abiraterone acetate composition to a medicine for treating prostatic cancer, so that the dosage can be reduced, and the individual difference of patients taking the medicine can be improved.
One of the purposes of the invention is realized by adopting the following technical scheme:
a nanometer abiraterone acetate composition comprises the following components in percentage by weight: (0.1-0.5): (0.05-0.5): (5-25): (5-25): (0-1) abiraterone acetate, a suspending agent, a surfactant, an antioxidant, a solvent and a diluent; in the composition, the D90 of the abiraterone acetate is less than or equal to 1000nm.
Further, the weight percentages of the abiraterone acetate, the suspending agent, the surfactant, the antioxidant, the solvent and the diluent are 1: (0.2-0.3): 0.1: (10-15): (10-15): (0-0.33).
Further, in the composition, the D90 of the abiraterone acetate is less than or equal to 1000nm, and can be one of the following values: 973nm, 793nm, 506nm, 950nm, 900nm, 850nm, 800nm, 750nm, 700nm, 650nm, 600nm, 550nm, 500nm; more preferably, the Abiraterone acetate has a D90 ≦ 400nm, which may be, for example, one of the following values: 400nm, 380nm, 343nm, 350nm and 300nm.
Further, in the composition, the D50 of the abiraterone acetate is less than or equal to 800nm, and can be one of the following values: 702nm, 564nm, 213nm, 206nm, 262nm, 800nm, 750nm, 650nm, 600nm, 550nm, 500nm, 450nm, 400nm, 350nm, 300nm, 250nm.
Further, in the composition, the D10 of the abiraterone acetate is less than or equal to 600nm, and can be one of the following values: 508nm, 409nm, 122nm, 127nm, 154nm, 600nm, 550nm, 450nm, 350nm, 300nm, 250nm, 200nm, 150nm.
In the present invention, D90 represents the particle size corresponding to the cumulative number of particle size distributions of the samples up to 90%; when D90 is not more than 1000nm, it means that 90% of particles having a particle size of 1000nm or less are present.
D50 represents the particle size corresponding to the cumulative percent particle size distribution of the sample at 50%. When D50 is less than or equal to 800nm, it means that 50% of the particles having a particle size of 800nm or less are present and 50% of the particles having a particle size of 800nm or more are present.
D10 represents the particle size corresponding to the cumulative number of particle size distributions of the samples reaching 10%. When D10 is less than or equal to 600nm, it means that 10% of the particles having a particle size of 600nm or less are present.
Further, in the composition, the polymer dispersity index PDI of the abiraterone acetate is less than or equal to 0.5, and can be 0.444, 0.372, 0.154, 0.146, 0.25, 0.35 and the like.
Further, the suspending agent is povidone, more preferably povidone K30 (PVP K30); the surfactant is sodium dodecyl sulfate (SLS) and/or docusate sodium; the antioxidant is any combination of Butylated Hydroxyanisole (BHA) and 2,6-ditertbutyl-p-cresol (BHT), more preferably, the antioxidant is equal mixture of BHA and BHT; the solvent is pure water; the diluent is lactose monohydrate.
The second purpose of the invention is realized by adopting the following technical scheme:
a preparation method of a nanometer abiraterone acetate composition comprises the following steps:
the preparation steps of the suspension are as follows: dividing the solvent with the formula amount into at least two parts, wherein one part is marked as a first solvent; adding the suspending agent and the surfactant according to the formula ratio into the first solvent, and stirring until the suspending agent and the surfactant are completely dissolved; then adding the abiraterone acetate with the formula amount, and uniformly stirring; adding the antioxidant with the formula amount under the stirring state, and uniformly stirring to obtain a suspension;
grinding: and transferring the suspension into a grinding machine for grinding to obtain an abiraterone acetate nano mixed solution. When the grinding is performed, the type of the grinding mill may be a bead mill, a planetary mill, a roll mill, or the like. The abrasive bodies are preferably zirconia grinding beads which may have a diameter of 0.5-10mm, preferably 0.5-1mm, more preferably YTZ zirconia grinding beads having a diameter of 0.65 mm. The grinding time and speed need to be preset to ensure that the abiraterone acetate nano mixed solution is obtained. The grinding speed is preferably 1500 to 3500rpm, more preferably 2000 to 3000rpm; the milling time is preferably from 5 minutes to 30 hours and may be selected from the following time periods: 5 minutes to 30 minutes, 10 minutes to 30 minutes, 1 hour to 5 hours, 8 hours to 15 hours, 9 hours to 24 hours.
Further, the method also comprises a dilution step, and the abiraterone acetate nanometer mixed solution is obtained and then diluted to obtain a diluted mixed solution. Upon dilution, one or more of a solvent, a stabilizer and a diluent may be added.
Further, a drying step is included, and after the diluted mixed solution is obtained, decompression freeze drying is carried out, so as to obtain the final product.
The third purpose of the invention is realized by adopting the following technical scheme:
a medicine containing a nano abiraterone acetate composition comprises the nano abiraterone acetate composition. In a specific implementation, a drug can be prepared from only the nano abiraterone acetate composition; or, in addition to the nanometer abiraterone acetate composition, pharmaceutically acceptable auxiliary materials are added to prepare the final medicine, and the auxiliary materials can be selected from one or more of excipient, flavoring agent, coloring agent, disintegrating agent and the like.
Further, the medicament is a tablet or a capsule.
Further, for a unit dose of the drug, 100mg to 280mg of nano abiraterone acetate is contained. For example, a unit dose of a drug comprising 280mg, 260mg, 240mg, 220mg, 200mg, 180mg, 160mg, 140mg, 120mg, 115mg, 105mg, 100mg of nano abiraterone acetate.
The fourth purpose of the invention is realized by adopting the following technical scheme:
the application of the nanometer abiraterone acetate composition in preparation of medicines for treating prostate cancer can improve individual difference of patients taking the medicines.
Compared with the prior art, the invention has the beneficial effects that:
(1) Compared with the existing abiraterone acetate on the market, the nanometer abiraterone acetate composition provided by the invention has the advantages that the particle size D90 of the abiraterone acetate is controlled within 1000nm, the bioavailability of the abiraterone acetate can be obviously improved, the rapid absorption of the medicine in the body is promoted, and the risks of large daily dose, food influence effect and individual difference of the existing abiraterone acetate tablets are solved. In addition, the composition also comprises auxiliary materials of a suspending agent, a surfactant, an antioxidant, a solvent and a diluent, and the components in the formula are reasonably matched, so that the dissolution rate and the stability of the abiraterone acetate can be ensured, and the bioavailability of the abiraterone acetate is improved.
(2) The preparation method of the nanometer abiraterone acetate composition provided by the invention is simple and convenient in process and high in success rate, and can solve the agglomeration problem of the abiraterone acetate nanometer suspension in the preparation process.
Drawings
FIG. 1 is a particle polarization microscope (PLM) map of a currently marketed abiraterone acetate drug substance;
fig. 2 is a particle polarization microscope (PLM) map of the milled abiraterone acetate nanosuspension in example 4 of the invention.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and the detailed description, and it should be noted that any combination of the embodiments or technical features described below can be used to form a new embodiment without conflict. The raw materials, equipments and the like used in the following examples are commercially available unless otherwise specified.
A nanometer abiraterone acetate composition comprises the following components in percentage by weight of 1: (0.1-0.5): (0.05-0.5): (5-25): (5-25): (0-1) abiraterone acetate, a suspending agent, a surfactant, an antioxidant, a solvent and a diluent; in the composition, the D90 of the abiraterone acetate is less than or equal to 1000nm.
Example 1
A nanometer abiraterone acetate composition has a formula shown in the following table 1.
Table 1 examples formulation table of nano abiraterone acetate composition
The nano abiraterone acetate composition of example 1 was prepared as follows:
155g of purified water is accurately measured at room temperature, placed in a beaker, added with 4g of PVP K30 and 2g of SLS under magnetic stirring, and stirred until the materials are completely dissolved to obtain an auxiliary material solution. Adding 20g of abiraterone acetate raw material medicine under stirring, dispersing the raw material medicine in the auxiliary material solution, and stirring uniformly. 100mg of BHA and 100mg of BHT were added while stirring, and the mixture was further stirred to obtain a suspension before grinding. The pre-mill suspension prepared was transferred to the circulation cylinder of a mill (already loaded with YTZ zirconia milling beads of diameter 0.65 mm). The inner wall of the beaker is washed with the remaining purified water in several times, and the washing solution is poured into a circulation cylinder. Starting grinding, adjusting the rotating speed to 3000rpm, grinding for 4 hours, stopping grinding, and discharging. Weighing, calculating the addition amount of lactose monohydrate according to the weight, adding 6.6g of lactose monohydrate under stirring, stirring for 10min to obtain a liquid medicine mother solution, diluting the liquid medicine mother solution by 1 time, and quickly freeze-drying under stirring to obtain the final product.
The final product of example 1 was reconstituted with a diluent and tested for particle size, the results of which are shown in table 2 below.
Table 2 example 1 particle size test results table
Example 2
A nanometer abiraterone acetate composition has a formula shown in the following table 3.
Table 3 formula of nano abiraterone acetate composition of example
261g of purified water is accurately measured at room temperature, placed in a beaker, and added with 6g of PVP K30 and 3g of SLS under magnetic stirring to be stirred until the PVP K30 and the SLS are completely dissolved, so that an auxiliary material solution is obtained. Adding 30g of abiraterone acetate raw material medicine under stirring, dispersing the abiraterone acetate raw material medicine in the auxiliary material solution, and stirring uniformly. 150mg of BHA and 150mg of BHT were added while stirring, and the mixture was further stirred to obtain a suspension before grinding. This suspension was transferred to the circulating cylinder of a mill (already equipped with YTZ zirconia grinding beads of diameter 0.65 mm). The inner wall of the beaker is washed by the residual purified water in several times, and the washing liquid is poured into a circulating cylinder. Starting grinding, adjusting the rotating speed to 3000rpm, and grinding for 24h. Weighing, calculating the addition amount of lactose monohydrate according to the weight, adding 6.6g of lactose monohydrate under stirring, and stirring for 10min to obtain the liquid medicine mother liquor. Diluting the solute of the mother liquid of the liquid medicine by one time, and then quickly freezing and drying to obtain the final product.
The final product of example 2 was reconstituted with a diluent and tested for particle size, the results of which are shown in table 4 below.
Table 4 example 2 particle size test results table
Example 3
A nano abiraterone acetate composition, the formula of which is shown in the following table 5.
Table 5 formulation of the nano abiraterone acetate composition of the examples
155g of purified water is accurately measured at room temperature, placed in a beaker, added with 4g of PVP K30 and 2g of SLS under magnetic stirring, and stirred until the materials are completely dissolved to obtain an auxiliary material solution. Adding 20g of abiraterone acetate raw material medicine under stirring, dispersing the raw material medicine in the auxiliary material solution, and stirring uniformly. 100mg of BHA and 100mg of BHT were added while stirring, and the mixture was further stirred to obtain a suspension before grinding. The pre-mill suspension prepared was transferred to the circulation cylinder of a mill (already loaded with YTZ zirconia milling beads of diameter 0.65 mm). The inner wall of the beaker is washed by the residual purified water in several times, and the washing liquid is poured into a circulating cylinder. Grinding is started, the rotating speed is adjusted to 3000rpm, grinding is stopped after 9 hours, discharging is carried out, and stirring is carried out for 10 minutes to obtain liquid medicine mother liquor. Diluting the mother liquid by 1 time, and quickly freeze-drying under stirring to obtain the final product.
The final product of example 3 was reconstituted with a diluent and tested for particle size, the results of which are shown in table 6 below.
Table 6 example 3 particle size test results table
Example 4
A nano abiraterone acetate composition, the formula of which is shown in table 7 below.
Table 7 formulation of the nano abiraterone acetate composition of the examples
155g of purified water is accurately measured at room temperature, placed in a beaker, added with 4g of PVP K30 and 2g of SLS under magnetic stirring, and stirred until the PVP K30 and the SLS are completely dissolved to obtain an auxiliary material solution. Adding 20g of abiraterone acetate raw material medicine under stirring, dispersing the raw material medicine in the auxiliary material solution, and stirring uniformly. 100mg of BHA and 100mg of BHT were added while stirring, and the mixture was further stirred to obtain a suspension before grinding. The pre-mill suspension prepared was transferred to the circulation cylinder of a mill (already loaded with YTZ zirconia milling beads of diameter 0.65 mm). The inner wall of the beaker is washed by the residual purified water in several times, and the washing liquid is poured into a circulating cylinder. Grinding is started, the rotating speed is adjusted to 2000rpm, grinding is stopped after 0.5h, discharging is carried out, and stirring is carried out for 10min to obtain liquid medicine mother liquor. Diluting the mother liquid by 1 time, and quickly freeze-drying under stirring to obtain the final product.
The final product of example 4 was reconstituted with a diluent and tested for particle size, the results of which are shown in Table 8 below.
Table 8 example 4 particle size test results table
Example 5
A nano abiraterone acetate composition, the formula of which is shown in table 9 below.
Table 9 formulation of the nano abiraterone acetate composition of the examples
155g of purified water is accurately measured at room temperature, placed in a beaker, added with 4g of PVP K30 and 2g of SLS under magnetic stirring, and stirred until the PVP K30 and the SLS are completely dissolved to obtain an auxiliary material solution. Adding 20g of abiraterone acetate raw material medicine under stirring, dispersing the raw material medicine in the auxiliary material solution, and stirring uniformly. 100mg of BHA and 100mg of BHT were added while stirring, and the mixture was further stirred to obtain a suspension before grinding. The pre-mill suspension prepared was transferred to the circulation cylinder of a mill (already loaded with YTZ zirconia milling beads of diameter 0.65 mm). The inner wall of the beaker is washed by the residual purified water in several times, and the washing liquid is poured into a circulating cylinder. Grinding is started, the rotating speed is adjusted to 2000rpm, grinding is stopped after 10min, discharging is carried out, and stirring is carried out for 10min to obtain liquid medicine mother liquor. Diluting the mother liquid by 1 time, and quickly freeze-drying under stirring to obtain the final product.
The final product of example 5 was reconstituted with a diluent and tested for particle size, the results of which are shown in Table 10 below.
Table 10 table for particle size test results of example 5
Effect verification
1. Pharmacokinetic protocol and results
1.1 pharmacokinetic protocol
1.11 design of the Experimental protocol
16 male SD rats were taken and given a single oral gavage, with the animals in the oral group fasted overnight (10-14 hours) prior to administration. The experimental design is shown in table 11 below.
TABLE 11 Experimental design
Note: the control group is a commercial abiraterone acetate sample which is not subjected to nano grinding and is prepared according to the formula of the composition.
1.12 preparation of test article
The preparation is carried out on the day of administration (about 1 hour before intragastric administration, and the suspension is shaken up before administration). Solvent: 0.4% sodium carboxymethylcellulose (CMC) in water.
1.13 modes of administration
The weight was weighed before administration, and the amount administered was calculated from the body weight. Administration is by intragastric administration.
1.14 blood sampling time points
PO blood sampling point 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 4hr, 8hr, 24hr.
1.15 plasma sample treatment
Blood is collected via jugular vein or other suitable means, with each sample collected at about 200 μ L/time point, anticoagulated with K2-EDTA, and placed on ice after collection. Blood samples were collected, placed on ice, and plasma was centrifuged within 1 hour (centrifugation conditions: 6800g,6 minutes, 2-8 ℃). Plasma samples were stored in a-80 ℃ freezer prior to analysis.
1.2 results of the experiment
The concentration of abiraterone in the plasma samples was determined using a validated LC-MS/MS analytical method. The main pharmacokinetic parameters of the drug were calculated from the plasma concentration data at different time points using Phoenix WinNonlin, and the main pharmacokinetic data of abiraterone in plasma are shown in Table 12.
Table 12 main pharmacokinetic parameters of abiraterone in plasma after oral administration (Mean ± SD, n = 4).
Analyzing the experimental data in table 12, fasted male rats dosed with 40mg/kg abiraterone in plasma of the test formulation (CJ-2103-03, D90=380 nm) had a Cmax of 176.76 ± 34.32ng/ml, an exposure AUC (0-t) of 963.01 ± 243.48h ng/ml, and an AUC (0- ∞) of 965.53 ± 235.00h ng/ml, which were 1.8, 2.0 and 1.96 times the dose of 40mg/kg control group (commercial abiraterone acetate drug substance), respectively. And the tested preparation CJ-2103-03 (example 3) has the advantage that the abiraterone acetate in the blood plasma has the rapid peak time, and the Tmax is 1.50 +/-1.19 h, so that the method provided by the embodiment of the invention can obviously improve the bioavailability of the abiraterone acetate by grinding the abiraterone acetate into a nano suspension, and can promote the rapid absorption of the drug in the body. Especially, when the particle size D90 of the nanosuspension is 380nm, the effect is the best, and the method is the best embodiment.
2. Polarizing microscope (PLM) testing
2.1A polarization microscope (PLM) test was performed on the currently available abiraterone acetate crude drug (a commercially available abiraterone acetate sample without nano-grinding, a control sample), and the test results are shown in FIG. 1.
As can be seen from fig. 1, the existing commercial abiraterone acetate bulk drug is in the form of lamellar crystals with non-uniform crystal size, and these characteristics affect the absorption and bioavailability of abiraterone acetate.
2.2 samples of example 4 were taken for polarization microscope (PLM) testing and the results are shown in FIG. 2.
As can be seen from fig. 2, compared with the existing commercial abiraterone acetate drug substance, the crystal particle size of the nanosuspension formed by grinding in example 4 is reduced from about 100 microns to below 1000nm compared with the crystal particle size of the unground abiraterone acetate drug substance. The particle size of the active ingredient abiraterone acetate was measured using a malvern laser particle size detector and the D90 was found to be 793nm. Combining the results in table 12, the exposure AUC (0-t) of abiraterone in plasma of fasting dosed male rat dose of the test formulations (example 4, cj-2103-04, D90=793 nm) was 811.59 ± 96.99h ng/ml, AUC (0- ∞) was 814.08 ± 178.08h ng/ml, which was 1.69 and 1.65 times higher than that of the unmilled control group (commercial abiraterone acetate drug substance), respectively. The embodiment of the invention shows that the bioavailability of the abiraterone acetate can be improved to different degrees by grinding the abiraterone acetate into nanosuspensions with different particle sizes.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.
Claims (10)
1. The nanometer abiraterone acetate composition is characterized by comprising the following components in percentage by weight of 1: (0.1-0.5): (0.05-0.5): (5-25): (5-25): (0-1) abiraterone acetate, a suspending agent, a surfactant, an antioxidant, a solvent and a diluent; in the composition, the D90 of the abiraterone acetate is less than or equal to 1000nm.
2. The nano abiraterone acetate composition of claim 1, wherein the weight percentages of the abiraterone acetate, the suspending agent, the surfactant, the antioxidant, the solvent and the diluent are 1: (0.2-0.3): 0.1: (10-15): (10-15): (0-0.33).
3. The nano abiraterone acetate composition of claim 1, wherein the D90 of the abiraterone acetate in the composition is 400nm or less.
4. The nano abiraterone acetate composition of claim 1, wherein the D50 of the abiraterone acetate in the composition is 800nm or less.
5. The nano abiraterone acetate composition of claim 1, wherein the D10 of the abiraterone acetate in the composition is 600nm or less.
6. The nano abiraterone acetate composition of claim 1, wherein the suspending agent is povidone; the surfactant is sodium dodecyl sulfate and/or docusate sodium; the antioxidant is any combination of butyl hydroxyanisole and 2,6-ditert-butyl paracresol; the solvent is pure water; the diluent is lactose monohydrate.
7. A method for preparing a nano abiraterone acetate composition of any of claims 1-6, comprising the steps of:
the preparation steps of the suspension are as follows: dividing the solvent with the formula amount into at least two parts, wherein one part is marked as a first solvent; adding the suspending agent and the surfactant according to the formula ratio into the first solvent, and stirring until the suspending agent and the surfactant are completely dissolved; then adding the abiraterone acetate with the formula amount, and uniformly stirring; adding the antioxidant with the formula amount under the stirring state, and uniformly stirring to obtain a suspension;
grinding: and transferring the suspension to a grinder for grinding to obtain the abiraterone acetate nano mixed solution.
8. A medicament containing a nano abiraterone acetate composition, which comprises the nano abiraterone acetate composition of any one of claims 1-6.
9. The drug containing a nano abiraterone acetate composition of claim 8, wherein for a unit dose of the drug, 100mg to 280mg of nano abiraterone acetate is included.
10. Use of the nano abiraterone acetate composition of any of claims 1-6 in the preparation of a medicament for treating prostate cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110643127.5A CN115444817A (en) | 2021-06-09 | 2021-06-09 | Nanometer abiraterone acetate composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110643127.5A CN115444817A (en) | 2021-06-09 | 2021-06-09 | Nanometer abiraterone acetate composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115444817A true CN115444817A (en) | 2022-12-09 |
Family
ID=84294971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110643127.5A Pending CN115444817A (en) | 2021-06-09 | 2021-06-09 | Nanometer abiraterone acetate composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115444817A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| CN106913538A (en) * | 2015-12-25 | 2017-07-04 | 山东新时代药业有限公司 | A kind of Abiraterone acetate sublingual tablets and preparation method thereof |
| CN111110646A (en) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | Prescription and preparation method of low-specification abiraterone acetate oral preparation |
| CN111617258A (en) * | 2019-02-28 | 2020-09-04 | 江苏恒瑞医药股份有限公司 | Method for preparing abiraterone or derivative pharmaceutical composition thereof and application thereof |
-
2021
- 2021-06-09 CN CN202110643127.5A patent/CN115444817A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| CN106913538A (en) * | 2015-12-25 | 2017-07-04 | 山东新时代药业有限公司 | A kind of Abiraterone acetate sublingual tablets and preparation method thereof |
| CN111617258A (en) * | 2019-02-28 | 2020-09-04 | 江苏恒瑞医药股份有限公司 | Method for preparing abiraterone or derivative pharmaceutical composition thereof and application thereof |
| CN111110646A (en) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | Prescription and preparation method of low-specification abiraterone acetate oral preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018241103B2 (en) | Abiraterone Acetate Formulation | |
| Kumar et al. | Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity | |
| CN101636150B (en) | Method for producing pulverized organic compound particle | |
| WO2014009436A1 (en) | Nanosuspension of abiraterone acetate | |
| CA2603189A1 (en) | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles | |
| AU2007312233A1 (en) | Micellar nanoparticles of chemical substances | |
| Wang et al. | Formulation and pharmacokinetics evaluation of puerarin nanocrystals for intravenous delivery | |
| CN104398477A (en) | Usnic acid nanometer suspension, and preparation method and use thereof | |
| CN103083235A (en) | Myricetin nanosuspension and preparation method thereof | |
| Wang et al. | Ginkgolides-loaded soybean phospholipid-stabilized nanosuspension with improved storage stability and in vivo bioavailability | |
| CN112261935A (en) | Injectable pharmaceutical composition and preparation method thereof | |
| CN111991355A (en) | Solid nanometer powder composition containing nanometer cannabidiol, preparation method and application | |
| CN110711176A (en) | Cilnidipine nanosuspension and preparation method thereof | |
| CN109568264B (en) | Andrographolide nanosuspension | |
| CN115444817A (en) | Nanometer abiraterone acetate composition and preparation method and application thereof | |
| CN109568265B (en) | Andrographolide nanosuspension | |
| CN105412022B (en) | A kind of ginkolide B fast release micropill and preparation method thereof | |
| US20070099996A1 (en) | Pharmaceutical compositions of acitretin | |
| CN108498455A (en) | A kind of water-soluble medicament nano crystalline substance of oiliness and preparation method thereof | |
| CN108175751B (en) | Bufogenin solid dispersion and preparation method thereof | |
| US20220395514A1 (en) | Low-dose celecoxib preparation | |
| CN109568266B (en) | Andrographolide nanosuspension | |
| CN106913538A (en) | A kind of Abiraterone acetate sublingual tablets and preparation method thereof | |
| CN107233348B (en) | Bufogenin nanocrystal and preparation method thereof | |
| CN104826120A (en) | Bosentan preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |